Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01933932
Recruitment Status : Active, not recruiting
First Posted : September 2, 2013
Results First Posted : August 29, 2017
Last Update Posted : June 25, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel

Condition or disease Intervention/treatment Phase
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV Drug: Selumetinib Drug: Docetaxel Drug: Placebo Drug: Pegylated G-CSF Phase 3

Detailed Description:
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT-1)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 510 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)
Actual Study Start Date : September 25, 2013
Actual Primary Completion Date : June 7, 2016
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Selumetinib + Docetaxel
Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
Drug: Selumetinib
Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
Other Name: AZD6244; ARRY-142886

Drug: Docetaxel
Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.

Drug: Pegylated G-CSF
All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
Other Name: Pegfilgrastim 6 mg

Experimental: Placebo + Docetaxel
Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
Drug: Docetaxel
Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.

Drug: Placebo
Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.

Drug: Pegylated G-CSF
All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
Other Name: Pegfilgrastim 6 mg




Primary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI) ]
    Progression free survival is defined as the time from randomisation until the date of objective disease progression (RECIST 1.1) or death (by any cause in the absence of progression)


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Measured at baseline until date of death due to any cause. Estimated final completion : approximately 3.5 years after FSI ]
    Overall Survival is defined as the time from the date of randomisation until death due to any cause.

  2. Objective Response Rate (ORR) [ Time Frame: Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI) ]
    ORR is defined as the number (%) of subjects with at least one overall visit response of complete response (CR) or partial response (PR). Per RECIST v1.1 for target lesions and assessed by CT/MRI: CR - disappearance of all target lesions; PR - >=30% decrease in the sum of the longest diameter of target lesion. (Non-target lesion and new lesion results are also taken into account for the overall visit result)

  3. Duration of Response (DoR) [ Time Frame: Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI) ]
    Duration of response is defined as the time from the date of first documented response until the date of objective disease progression (RECIST 1.1) or death (by any cause in the absence of progression)

  4. Symptom Improvement Rate Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS) [ Time Frame: Measured from date of randomisation until 30 days post treatment discontinuation or 30 days post progression (if study treatment is discontinued before progression). Estimated final completion : approximately 3 years after first subject in (FSI) ]
    The symptom improvement rate will be defined as the number (%) of patients with two consecutive assessments at least 18 days apart (ie 21 days allowing a visit window of 3 days) which showed a clinically meaningful improvement in symptoms from baseline (defined as a decrease in the ASBI from baseline ≥10). LCSS-Lung Cancer Symptom Scale; ASBI-Average symptom burden index.

  5. Time to Symptom Progression Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS) [ Time Frame: Measured from date of randomisation until 30 days post treatment discontinuation or 30 days post progression (if study treatment is discontinued before progression). Estimated final completion : approximately 3 years after first subject in (FSI) ]
    Time to symptom progression will be defined as the time from randomization until the date of first clinically meaningful symptom deterioration (defined as an increase in the ASBI from baseline ≥10), or death (by any cause). LCSS-Lung Cancer Symptom Scale; ASBI-Average symptom burden index.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed, written and dated informed consent prior to any study specific procedures
  • Male or female, aged 18 years or older
  • Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)
  • KRAS mutation positive tumour sample as determined by the designated testing laboratory
  • Failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy

Exclusion Criteria:

  • Mixed small cell and non-small cell lung cancer histology.
  • Received >1 prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
  • Receiving or have received systemic anti-cancer therapy within 30 days prior to starting study treatment
  • Other concomitant anti-cancer therapy agents excepts steroids
  • Prior treatment with a Mitogen-Activated protein Kinase (MEK) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable).
  • Last radiation therapy within 4 weeks prior starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01933932


  Hide Study Locations
Locations
Layout table for location information
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
United States, Florida
Research Site
Pembroke Pines, Florida, United States, 33028
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30318
United States, Illinois
Research Site
Chicago, Illinois, United States, 60637
United States, Louisiana
Research Site
Metairie, Louisiana, United States, 70006
United States, Massachusetts
Research Site
Boston, Massachusetts, United States, 02114
Research Site
Boston, Massachusetts, United States, 02215
Research Site
Danvers, Massachusetts, United States, 01923
United States, New York
Research Site
New York, New York, United States, 10011
Research Site
New York, New York, United States, 10032
United States, North Carolina
Research Site
Durham, North Carolina, United States, 27710
United States, Pennsylvania
Research Site
Hershey, Pennsylvania, United States, 17022
Research Site
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 37203
Research Site
Nashville, Tennessee, United States, 37232
United States, Washington
Research Site
Seattle, Washington, United States, 98104
United States, West Virginia
Research Site
Morgantown, West Virginia, United States, 26506
Argentina
Research Site
Buenos Aires, Argentina, 1426
Research Site
Buenos Aires, Argentina, C1025ABI
Research Site
Ciudad de Buenos Aires, Argentina, 1180
Research Site
Cordoba, Argentina, 5000
Research Site
Rosario, Argentina, S2000KZE
Australia
Research Site
Camperdown, Australia, 2050
Research Site
Chermside, Australia, 4032
Research Site
Darlinghurst, Australia, 2010
Research Site
Fitzroy, Australia, 3065
Research Site
Kogarah, Australia, 2217
Research Site
Kurralta Park, Australia, 5037
Research Site
Malvern, Australia, 3144
Research Site
Wendouree, Australia, 3355
Research Site
Woodville South, Australia, 5011
Austria
Research Site
Innsbruck, Austria, 6020
Research Site
Linz, Austria, 4020
Research Site
Salzburg, Austria, 5020
Research Site
Vienna, Austria, 1160
Research Site
Wien, Austria, 1100
Belgium
Research Site
Brussels, Belgium, 1090
Research Site
Bruxelles, Belgium, 1000
Research Site
Bruxelles, Belgium, 1200
Research Site
Gent, Belgium, 9000
Research Site
Leuven, Belgium, 3000
Research Site
Roeselare, Belgium, 8800
Brazil
Research Site
Barretos, Brazil, 14784-400
Research Site
Ijuí, Brazil, 98700-000
Research Site
Pelotas, Brazil, 096015-280
Research Site
Porto Alegre, Brazil, 90035-003
Research Site
Porto Alegre, Brazil, 90610-000
Research Site
Sao Paulo, Brazil, 01209-000
Research Site
Sao Paulo, Brazil, 01246-000
Research Site
Sao Paulo, Brazil
Research Site
São José do Rio Preto, Brazil, 15090-000
Bulgaria
Research Site
Plovdiv, Bulgaria, 4000
Research Site
Sofia, Bulgaria, 1233
Research Site
Sofia, Bulgaria, 1303
Research Site
Sofia, Bulgaria, 1330
Research Site
Varna, Bulgaria, 9010
Research Site
Vratza, Bulgaria, 3000
Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Research Site
Kelowna, British Columbia, Canada, V1Y 5L3
Research Site
Surrey, British Columbia, Canada, V3V 1Z2
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Research Site
Oshawa, Ontario, Canada, L1G 2B9
Research Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Research Site
Montreal, Quebec, Canada, H4A 3J1
Canada, Saskatchewan
Research Site
Regina, Saskatchewan, Canada, S4T 7T1
Research Site
Saskatoon, Saskatchewan, Canada, S7N 4H4
Canada
Research Site
Quebec, Canada, G1V 4G5
Chile
Research Site
Santiago, Chile, 7500921
Research Site
Santiago, Chile, 7520349
Research Site
Santiago, Chile, 7630370
Research Site
Santiago, Chile, 8360160
Research Site
Santiago, Chile, 8380456
Research Site
Santiago, Chile, 8420383
France
Research Site
Brest Cedex, France, 29609
Research Site
Caen, France, F-14033
Research Site
Clermont Ferrand, France, 63003
Research Site
Dijon, France, 21079
Research Site
Lille Cedex, France, 59020
Research Site
Marseille Cedex 20, France, 13915
Research Site
Paris, France, 75020
Research Site
Pierre Benite Cedex, France, 69310
Research Site
RENNES Cedex 9, France, 35033
Research Site
Toulouse, France, 31059
Germany
Research Site
Augsburg, Germany, 86156
Research Site
Bad Berka, Germany, 99437
Research Site
Dortmund, Germany, 44309
Research Site
Gerlingen, Germany, 70839
Research Site
Großhansdorf, Germany, 22927
Research Site
Halle, Germany, 06120
Research Site
Heidelberg, Germany, 69126
Research Site
Homburg, Germany, 66424
Research Site
Köln, Germany, 50937
Research Site
Löwenstein, Germany, 74245
Research Site
Moers, Germany, 47441
Research Site
München, Germany, 81925
Research Site
Ulm, Germany, 89081
Research Site
Wiesbaden, Germany, 65199
Research Site
Würzburg, Germany, 97080
Hungary
Research Site
Budapest, Hungary, 1121
Research Site
Budapest, Hungary, 1122
Research Site
Edelény, Hungary, 3780
Research Site
Győr, Hungary, 9024
Research Site
Kaposvár, Hungary, 7400
Research Site
Miskolc, Hungary, 3529
Research Site
Nyíregyháza, Hungary, 4412
Research Site
Törökbálint, Hungary, 2045
Israel
Research Site
Beer Sheva, Israel, 8410101
Research Site
Haifa, Israel, 31096
Research Site
Kfar Saba, Israel, 4428164
Research Site
Petah Tikva, Israel, 49100
Research Site
Tel Hashomer, Israel, 52621
Research Site
Tel-Aviv, Israel, 64239
Italy
Research Site
Bari, Italy, 70124
Research Site
Genova, Italy, 16100
Research Site
Livorno, Italy, 57100
Research Site
Milano, Italy, 20132
Research Site
Napoli, Italy, 80131
Research Site
Orbassano, Italy, 10043
Research Site
Parma, Italy, 43100
Research Site
Perugia, Italy, 06132
Research Site
Roma, Italy, 00128
Research Site
Roma, Italy, 00144
Mexico
Research Site
Mexico, Mexico, 14080
Research Site
Monterrey, Mexico, 64460
Netherlands
Research Site
Amsterdam, Netherlands, 1066 CX
Research Site
Amsterdam, Netherlands, 1081 HV
Research Site
Bergen Op Zoom, Netherlands, 4624 VT
Research Site
Den Bosch, Netherlands, 5223 GZ
Research Site
Maastricht, Netherlands, 6202 AZ
Peru
Research Site
Lima, Peru, 15033
Research Site
Lima, Peru, 15073
Research Site
Lima, Peru, L27
Research Site
Lima, Peru, LIMA 01
Research Site
Lima, Peru, LIMA 11
Research Site
Lima, Peru, LIMA 29
Research Site
Lima, Peru, LIMA 34
Research Site
Miraflores, Peru, 15046
Poland
Research Site
Brzozow, Poland, 36-200
Research Site
Bydgoszcz, Poland, 85-796
Research Site
Gdańsk, Poland, 80-219
Research Site
Gdańsk, Poland, 80-952
Research Site
Grudziądz, Poland, 86-300
Research Site
Kraków, Poland, 31-202
Research Site
Lubin, Poland, 59-301
Research Site
Olsztyn, Poland, 10-357
Research Site
Opole, Poland, 45-061
Research Site
Sucha Beskidzka, Poland, 34-200
Research Site
Szczecin, Poland, 70-891
Research Site
Warszawa, Poland, 02-781
Portugal
Research Site
Amadora, Portugal, 2720-276
Research Site
Coimbra, Portugal, 3040-316
Research Site
Lisboa, Portugal, 1099-023
Research Site
Lisboa, Portugal, 1769-001
Research Site
Porto, Portugal, 4100-180
Research Site
Porto, Portugal, 4200-319
Research Site
Vila Nova de Gaia, Portugal, 4434-502
Romania
Research Site
Cluj Napoca, Romania, 400015
Research Site
Cluj Napoca, Romania, 400058
Russian Federation
Research Site
Kazan, Russian Federation, 420012
Research Site
Moscow, Russian Federation, 105229
Research Site
Moscow, Russian Federation, 121309
Research Site
Saint Petersburg, Russian Federation, 197342
Research Site
Saint Petersburg, Russian Federation, 197758
Research Site
Saint-Petersburg, Russian Federation, 194291
Research Site
Volgograd, Russian Federation, 400138
Spain
Research Site
Barcelona, Spain, 08003
Research Site
Barcelona, Spain, 08035
Research Site
Madrid, Spain, 28034
Research Site
Madrid, Spain, 28041
Research Site
Málaga, Spain, 29010
Research Site
Sevilla, Spain, 41013
Research Site
Vigo(Pontevedra), Spain, 36204
Research Site
Zaragoza, Spain, 50009
Sweden
Research Site
Linköping, Sweden, 581 85
Research Site
Uppsala, Sweden, SE-751 85
Research Site
Örebro, Sweden, 701 85
Turkey
Research Site
Ankara, Turkey, 06230
Research Site
Ankara, Turkey, 06280
Research Site
Istanbul, Turkey, 34662
Research Site
İstanbul, Turkey, 34844
Research Site
Izmir, Turkey, 35100
Research Site
Izmir, Turkey, 35110
Research Site
Manisa, Turkey, 45030
Ukraine
Research Site
Chernivtsi, Ukraine, 58013
Research Site
Dnipropetrovsk, Ukraine, 49102
Research Site
Kharkiv, Ukraine, 61070
Research Site
Kryvyi Rih, Ukraine, 50048
Research Site
Kyiv, Ukraine, 03115
Research Site
Sumy, Ukraine, 40022
Research Site
Uzhgorod, Ukraine, 88000
Research Site
Zaporizhzhya, Ukraine, 69040
United Kingdom
Research Site
Aberdeen, United Kingdom, AB2 2ZB
Research Site
London, United Kingdom, SW3 6JJ
Research Site
Manchester, United Kingdom, M20 4BX
Research Site
Nottingham, United Kingdom, NG5 1PB
Research Site
Sutton, United Kingdom, SM2 5PT
Research Site
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Chair: Gabriella Mariani, MD AstraZeneca UK, MSD
Principal Investigator: Pasi Jänne, MD Dana-Faber Cancer Institute, USA

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01933932     History of Changes
Other Study ID Numbers: D1532C00079
2013-001676-38 ( EudraCT Number )
First Posted: September 2, 2013    Key Record Dates
Results First Posted: August 29, 2017
Last Update Posted: June 25, 2019
Last Verified: June 2019

Keywords provided by AstraZeneca:
Mitogen-Activated Protein Kinase Kinase inhibitor; Non Small Cell Lung Cancer; metastatic; second line treatment for Non Small Cell Lung Cancer; KRAS mutation

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action